1. No category

Page 1 of 1
Quantitative Equity Report | Release: 28 Dec 2015, 23:01, GMT-06:00 | Reporting Currency: EUR | Trading Currency: EUR
Neuron Bio SA NEU
Last Close 28 Dec 2015
Quantitative Fair Value Est 28 Dec 2015
Market Cap 28 Dec 2015
Sector
Industry
1.54
1.85
10.6 Mil
d Healthcare
Biotechnology
Neuron Bio SA, through its divisions, is engaged in the
development of bio solutions for the pharmaceutical and agrofood industries.
Country of Domicile
ESP Spain
Price Versus Quantitative Fair Value
2011
2012
2013
2014
2015
2016
Sales/Share
Forecast Range
Forcasted Price
Dividend
Split
Quantitative Fair Value Estimate
10
Total Return
Quantitative Scores
8
Scores
Momentum:
—
Standard Deviation: 85.23
Liquidity: Medium
All Rel Sector Rel Country
Quantitative Moat
None
Valuation
Undervalued
Quantitative Uncertainty Very High
Financial Health
Moderate
30
82
43
13
37
68
41
5
6
25
83
28
3
4
1.29
52-Wk
3.28
0.64
5-Yr
4.16
2
NEU
d
ESP
Undervalued
Fairly Valued
Overvalued
Source: Morningstar Equity Research
Valuation
Sector
Median
Country
Median
—
—
—
—
—
—
—
—
0.88
27.5
12.4
18.6
28.0
1.41
3.3
4.0
0.91
17.1
13.2
8.8
14.6
2.74
1.5
1.1
Current 5-Yr Avg
Sector
Median
Country
Median
12.5
6.7
306.4
Current 5-Yr Avg
Price/Quant Fair Value
Price/Earnings
Forward P/E
Price/Cash Flow
Price/Free Cash Flow
Dividend Yield %
Price/Book
Price/Sales
0.83
—
—
—
—
—
1.2
131.7
Profitability
Return on Equity %
Return on Assets %
Revenue/Employee (K)
-12.3
-4.2
3.3
-10.1
-3.8
6.4
Quantitative Moat
-30.0
-16.0
14.3
-3.4
-35.4
-50.9
48.4
52.1
-33.0
-32.9
—
-14.1
38.8
—
104.2
51.0
—
41.8
54.1
—
-19.8
59.2
—
-12.9
131.7
Total Return %
+/– Market (Morningstar World
Index)
Dividend Yield %
Price/Earnings
Price/Revenue
Morningstar RatingQ
QQQQQ
QQQQ
QQQ
QQ
Q
Financials (Fiscal Year in K)
Revenue
% Change
2010
2011
2012
2013
2014
TTM
250
-47.9
418
67.2
200
-52.1
53
-73.5
157
196.7
76
-51.6
-1,617
—
-404
-2,121
—
-631
-2,020
—
99
-1,924
—
-1,139
-2,468
—
-2,552
-2,523
—
-1,190
10.5
2.9
275.9
-3,046
-2,092
-5,138
-2,054.1
-3,567
-2,933
-6,500
-1,553.8
-1,172
-3,487
-4,659
-2,326.6
54
-4,032
-3,978
-7,495.1
-2,769
-688
-3,457
-2,195.4
-2,769
-688
-3,457
-4,532.8
Score
100
-0.09
-231.1
-0.81
-0.14
—
-0.91
0.02
—
-1.09
-0.26
-1,220.6
-0.46
-0.37
—
-0.84
-0.12
—
-0.35
EPS
% Change
Free Cash Flow/Share
—
2.39
4,625
—
2.21
4,263
—
2.38
4,391
—
2.01
6,881
—
1.64
—
—
1.17
6,881
Dividends/Share
Book Value/Share
Shares Outstanding (K)
-4.4
-2.5
-161.3
0.02
1.7
-6.7
-3.2
-150.9
0.02
2.8
1.1
0.4
49.3
0.01
2.4
-11.8
-4.5
-2,145.9
0.00
2.9
-27.7
-9.0
-1,620.6
0.01
3.3
-12.3
-4.2
-1,560.4
0.00
3.5
Profitability
Return on Equity %
Return on Assets %
Net Margin %
Asset Turnover
Financial Leverage
735.5
-646.5
1,874
503.2
-507.1
2,433
526.7
-1,008.9
1,257
1,589.6
-3,624.6
1,112
361.0
-1,567.3
9,989
741.4
-3,308.3
—
Gross Margin %
Operating Margin %
Long-Term Debt
11,196
0.1
7,569
0.1
10,148
0.0
9,149
0.0
9,289
0.0
8,080
0.0
80
Operating Income
% Change
Net Income
Operating Cash Flow
Capital Spending
Free Cash Flow
% Sales
60
40
20
0
2008
2009
2010
2011
2012
2013
2014
Financial Health
Current 5-Yr Avg
Distance to Default
Solvency Score
Assets/Equity
Long-Term Debt/Equity
0.2
896.5
3.3
1.1
—
—
2.6
0.4
2015
Sector
Median
Country
Median
0.6
501.0
1.4
0.1
0.6
628.2
2.7
0.3
Growth Per Share
Revenue %
Operating Income %
Earnings %
Dividends %
Book Value %
Stock Total Return %
1-Year
3-Year
5-Year
10-Year
196.7
—
—
—
-35.2
-24.5
-27.8
—
—
—
-14.3
-13.7
-20.0
—
—
—
-9.2
-11.1
—
—
—
—
—
—
Semi-Annual Revenue & EPS
Revenue (K)
Mar
Jun
2015
—
69.7
2014
—
150.9
2013
—
21.1
2012
—
95.4
Earnings Per Share ()
2015
—
0.10
2014
—
-0.15
2013
—
-0.29
2012
—
-0.31
Total Equity
Fixed Asset Turns
Revenue Growth Year On Year %
Sep
—
—
—
—
Dec
—
6.6
32.0
104.9
Total
—
157.5
53.1
200.3
—
—
—
—
—
-0.22
0.03
0.33
—
-0.37
-0.26
0.02
615.2
192.6
0.4
-41.7
2011
2012
-58.8
-77.9
2013
© Morningstar 2015. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and
opinions presented herein do not constitute investment advice; are provided solely for informational purposes and therefore is not an offer to buy or sell a security; are not warranted to be correct, complete or accurate; and
are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data,
analyses or opinions or their use. The information herein may not be reproduced, in any manner without the prior written consent of Morningstar. Please see important disclosures at the end of this report.
-69.5
-79.5
2014
-53.8
2015
®
ß